This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Tay-Sachs Disease / GM2 Gangliosidosis / HEXA Deficiency / Hexosaminidase A Deficiency테이-삭스병 / GM₂-강글리오시드증 / 연소형 GM₂-강글리오시드증 / 성인형 GM₂-강글리오시드증 / GM₂-강글리오시드증 NOS

Contents and key points
ItemDetails
A. Classification codesICD-10: E75.0 (GM₂ gangliosidosis) | Special Copayment Reduction: V117 (ultra-rare disease)
B. SynonymsTay-Sachs disease, GM2 gangliosidosis type 1, juvenile GM2 gangliosidosis, adult GM2 gangliosidosis, GM2 gangliosidosis NOS, Hexosaminidase A (HexA) deficiency, HEXA deficiency, B variant GM2 gangliosidosis, Infantile/juvenile/adult-onset GM2 gangliosidosis
C. Adult onsetPossible first onset in adulthood: yes (juvenile and adult forms) — the classic infantile form manifests at 3~6 months of age. In the juvenile form, neurological symptoms first appear at 2~10 years; in the adult (late-onset) form, in the teens to 30s or later. Patients with the adult form often first present with spinocerebellar ataxia, proximal muscle weakness, or psychiatric symptoms, and diagnostic delay is common.
1. History1881 Warren Tay described the cherry-red spot on the fundus. 1887 Bernard Sachs described the nervous system and hereditary findings. 1969 O'Brien and Sandhoff identified HexA deficiency. 1985 HEXA gene cloned.
2. CausesPathogenic variants in the HEXA gene (15q23-q24) → hexosaminidase A (HexA) deficiency → inability to degrade GM₂ ganglioside in lysosomes → GM₂ accumulation in neurons → neuronal death.
3. GeneticsAutosomal recessive. HEXA gene at 15q23-q24. Three founder variants are highly frequent in Ashkenazi Jews. Residual HexA activity determines the phenotype (infantile, juvenile, adult).
4. General epidemiologyPrevalence in the general population about 1/100,000~1/300,000. Markedly higher in Ashkenazi Jewish, French Canadian, and Cajun populations (carrier frequency 1/30).
5. PathophysiologyHexA (αβ heterodimer) deficiency → inability to degrade GM₂ ganglioside in lysosomes → lysosomal GM₂ accumulation in neurons → neuronal swelling, apoptosis, and collapse of neural circuits. Deficiency of GM₂ activator protein (GM2AP) causes the AB variant.
6. SymptomsInfantile form (onset at 3~6 months): hyperacusis, developmental regression, hypotonia, cherry-red spot (retina), epilepsy, progressive neurological deterioration, death around age 4. Juvenile form: onset at 2~10 years, ataxia, cognitive decline, spasticity. Adult form: spinocerebellar ataxia, proximal muscle weakness, psychiatric symptoms.
7. SignsCherry-red spot (90% of the infantile form). Hypotonia → spasticity. Fundus findings. Brain MRI: hyperintensity of the basal ganglia (T2). Decreased HexA enzyme activity. Elevated CSF GM₂.
8. ScreeningCarrier screening program in high-risk populations (Ashkenazi Jews). Infants: immediate HexA enzyme testing when developmental regression plus a cherry-red spot is found. Adult form: HexA screening for spinocerebellar ataxia of unknown cause plus muscle weakness.
9. DiagnosisMeasurement of HexA enzyme activity (serum, leukocytes, fibroblasts). HEXA molecular genetic testing (confirmation). Brain MRI. Nerve conduction studies and visual evoked potentials. Confirmatory protocols by phenotype after birth.
10. TreatmentCurrently no curative treatment for the infantile and juvenile forms (palliative care is central). Adult form: symptom management (anticonvulsants, muscle relaxants, psychiatric medications). Phase 1/2 clinical trials of AAV dual-vector gene therapy are ongoing (encouraging early results in 2025). Substrate reduction therapy under investigation.
11. PrognosisInfantile form: death around age 4. Juvenile form: death in adolescence. Adult form: survival of several decades is possible but with progressive neurological disability. Improvement in future prognosis is expected depending on gene therapy clinical trial results.
12. PreventionCarrier screening program in high-risk populations. Genetic counseling, prenatal genetic testing, and preimplantation genetic testing (PGT-M). Early formation of a palliative care team.
13. ReferencesTay W (1881), Sachs B (1887), O'Brien JS (1969) and 7 others.

1. History

Tay-Sachs disease is one of the first lysosomal storage diseases to be clinically described in history, and it was named after two pioneering physicians. In 1881, the British ophthalmologist Warren Tay (1843~1927) was the first to describe, in the fundus of an infant with developmental regression, a cherry-red spot in the macular region surrounded by a white ring, and published it in the Transactions of the Ophthalmological Society. This finding was later established as a diagnostic marker of neuronal storage diseases.

In 1887, the New York neurologist Bernard Sachs (1858~1944) systematically described the neurological findings of the same disease. Sachs noted that the disease occurs in a concentrated manner in Eastern European Jewish (Ashkenazi Jewish) families and was the first to clearly describe it as familial and hereditary. Sachs named the disease 'familial amaurotic idiocy', but it later came into common use as 'Tay-Sachs disease', combining the names of the two physicians who first described it.

The biochemical mechanism of the disease was unknown until the mid-20th century. In 1969, John S. O'Brien of the University of California discovered that activity of the lysosomal enzyme hexosaminidase A (HexA) is deficient in patients with Tay-Sachs disease and established that this is the direct cause of GM₂ ganglioside accumulation. At about the same time, Konrad Sandhoff described Sandhoff disease, in which both HexA and HexB are deficient, revealing the molecular heterogeneity of GM₂ gangliosidosis.

In 1985 the HEXA gene was cloned, and as a high carrier frequency (about 1/30) was confirmed in the Ashkenazi Jewish population, a large-scale carrier screening program for this population was introduced. This screening program reduced the incidence of Tay-Sachs disease in the Ashkenazi Jewish population by more than 90%, which is regarded as one of the most successful examples of genetic disease prevention in human history.

Since the 2000s, it has become widely recognized that adult GM₂ gangliosidosis (late-onset Tay-Sachs, LOTS) presents in young and middle adulthood with spinocerebellar ataxia, proximal muscle weakness, and psychiatric symptoms. A small number of Tay-Sachs disease cases have also been reported in Korea, and it is included in the Korea Disease Control and Prevention Agency (KDCA) list of ultra-rare diseases. In 2025, encouraging early results from a phase 1/2 clinical trial of AAV dual-vector gene therapy were announced, raising expectations for curative treatment.


2. Causes

Tay-Sachs disease (GM₂ gangliosidosis type B) is an autosomal recessive lysosomal storage disease caused by pathogenic variants in the HEXA gene (15q23-q24), resulting in deficient or markedly reduced activity of the lysosomal enzyme hexosaminidase A (HexA). HexA has an αβ heterodimer structure composed of an α subunit and a β subunit; the α subunit is encoded by the HEXA gene and the β subunit by the HEXB gene. Because the α subunit of HexA is essential for cleaving the N-acetylgalactosamine (GalNAc) residue of GM₂ ganglioside, HEXA variants cause loss of HexA function only.

When HexA is deficient, the degradation of GM₂ ganglioside is blocked in lysosomes. GM₂ is mainly a component of neuronal cell membranes and is normally degraded to GM₃ in lysosomes through the cooperative action of HexA and the GM2 activator protein (GM2AP). When HexA is deficient, GM₂ is not degraded and accumulates in large amounts in neuronal lysosomes, disrupting cell function and causing cell death (apoptosis, necrosis).

GM₂ gangliosidosis has three variants depending on the gene involved. B variant (Tay-Sachs disease): HEXA variant → HexA deficiency (α subunit deficiency, HexB normal). O variant (Sandhoff disease): HEXB variant → deficiency of both HexA and HexB (because the β subunit is shared, both HexA and HexB are lost). AB variant: variant in the GM2A gene (GM2 activator protein) → HEXA and HEXB both normal but GM₂ cannot be degraded.

More than 150 pathogenic variants have been reported in the HEXA gene to date. Phenotypic diversity depends largely on residual HexA activity. Variants with HexA activity < 0.1% of normal (essentially absent) cause the severe infantile phenotype. A residual activity of about 0.5% produces the juvenile form, and about 2~4% produces the adult (late-onset) form.


3. Genetics

Tay-Sachs disease is inherited in an autosomal recessive manner. The HEXA gene is located on the long arm of chromosome 15 (15q23-q24) and consists of 14 exons. The α subunit protein consists of 529 amino acids and contains four N-glycosylation sites and catalytic residues (Glu323, Tyr456). The HexA enzyme belongs to the β-N-acetylhexosaminidase family and, besides GM₂ ganglioside, binds GM2AP and degrades various substrates.

Three major founder variants are found at high frequency in the Ashkenazi Jewish population. (1) 1278insTATC (c.1278_1279insTATC): a 4-base insertion in exon 11 causing a frameshift, the most common infantile-form variant. Frequency about 75~80% in this population. (2) IVS12+1G>C (c.1421+1G>C): an intron 12 splice site variant found in the infantile or adult form. (3) G269S (c.805G>A): a mild missense variant associated with the adult (late-onset) form. These three variants account for about 95~98% of Tay-Sachs disease in Ashkenazi Jews. The carrier frequency in this population is about 1/30, more than 10 times higher than in the general population (1/300~1/380).

In French Canadians (Quebec population), the IVS7+1A>G variant, in addition to 1278insTATC, shows a high frequency because of a founder effect. The 1278insTATC variant is also frequent in the Cajun population (Louisiana). In the general population, various missense, frameshift, and splice variants are found.

Genotype-phenotype correlation: when both alleles carry variants that completely abolish HexA (nonsense, frameshift, large deletion), the severe infantile phenotype results. When the G269S missense variant is present on one or both alleles, the adult (late-onset) phenotype results. The level of residual enzyme activity is the key determinant of the phenotype. Carriers (heterozygotes, HEXA activity about 50%) have no clinical symptoms.


4. General epidemiology

The general population prevalence of Tay-Sachs disease (infantile GM₂ gangliosidosis) is estimated at about 1/100,000~1/300,000 births. However, prevalence differs markedly by ethnic background.

In the Ashkenazi Jewish population, the carrier frequency is about 1/30, and the prevalence in this population is about 1/3,600 births, more than 100 times higher than in the general population. In French Canadians (Quebec population), the carrier frequency is also high at about 1/30 because of a founder effect. A similarly high frequency is reported in the Cajun (Louisiana) population. The carrier frequency in the general population excluding these groups is about 1/300.

A carrier screening program for Ashkenazi Jews began in the United States and Israel in the 1970s and reduced the incidence of Tay-Sachs disease in this population by more than 90%. This is a historic example demonstrating the effectiveness of carrier screening programs in the prevention of genetic diseases.

Following autosomal recessive inheritance, the sex distribution is equal in males and females. Adult (late-onset) Tay-Sachs disease can occur in any ethnic group, and in non-Ashkenazi Jewish populations it often occurs in compound heterozygotes of the G269S variant and other non-founder variants.

In Korea, Tay-Sachs disease is registered with the KDCA Rare Disease Helpline, and a small number of confirmed cases have been reported. The Ashkenazi Jewish-specific founder variants are rare in Koreans, and various missense or frameshift variants are found in Korean patients. Cases of the adult form are sometimes found in neurology rather than pediatrics.


5. Pathophysiology

The core pathophysiology of Tay-Sachs disease is the accumulation of GM₂ ganglioside within neurons due to deficiency of the lysosomal enzyme HexA.

Normal metabolism of GM₂ ganglioside: gangliosides are glycolipids abundant in cell membranes, especially in the exoplasmic leaflet of neuronal membranes, and are involved in intercellular signaling, cell recognition, and regulation of signal transduction. GM₂ is a glycolipid containing one sialic acid and one N-acetylgalactosamine (GalNAc). Normal ganglioside degradation occurs when endosomal vesicles fuse with lysosomes, and GM₂ is degraded to GM₃ through the cooperative action of HexA (αβ heterodimer) and GM2AP (activator protein). GM2AP is a lipid-transport accessory protein that extracts membrane-bound GM₂ into the soluble environment of the lysosome and promotes its contact with HexA.

When HexA is deficient (HEXA variant), this degradation process is blocked and GM₂ accumulates in lysosomes. GM₂ accumulation is prominent in neurons, especially cerebellar granule cells, cerebral cortical neurons, spinal motor neurons, and retinal ganglion cells. Lysosomal GM₂ accumulation triggers the following cascade: (1) lysosomal dysfunction → reduced function of other lysosomal enzymes → impaired autophagy. (2) Formation of cytoplasmic cysts and vacuoles → cellular swelling. (3) Increased oxidative stress → abnormal intracellular signaling → disturbed calcium homeostasis. (4) Activation of apoptotic signals (Bax, caspase-3) → neuronal death. As a result of neuronal death, the neural circuits of the cerebellum, cerebral cortex, basal ganglia, and brainstem progressively collapse, causing loss of neurological function.

Mechanism of cherry-red spot formation: around the macula of the retina, ganglion cells are densely packed in multiple layers. When GM₂ accumulates in these ganglion cells, the cells swell and become opaque. Because the fovea centralis of the macula has no ganglion cells, the red color of the retinal pigment epithelium shows through, and contrasts with the white, swollen surrounding ganglion cells, appearing as a cherry-red spot.


6. Symptoms

Tay-Sachs disease (GM₂ gangliosidosis) is classified into three clinical phenotypes according to residual HexA activity.

Infantile form (Classic Tay-Sachs): symptoms begin at 3~6 months of age and progress rapidly. Regression of developmental milestones is observed in an infant who had been developing normally. The most characteristic early symptom is hyperacusis, with an exaggerated startle response to sudden loud sounds (clapping, door closing). Motor regression (loss of the ability to sit and crawl), hypotonia, decreased vision, and abnormal eye movements follow. A cherry-red spot is identified on fundus examination at 6~10 months of age. Seizures occur, neurodegeneration accelerates, and by 2~3 years of age a state of complete unresponsiveness close to a vegetative state is reached. Most patients die before age 4~5 from complications such as pneumonia.

Juvenile form: developmental regression begins at 2~10 years of age. Ataxia, dysarthria, spasticity, and cognitive decline progress gradually. The cherry-red spot may be less distinct than in the infantile form or absent. Patients often reach a vegetative state in adolescence and die at around 10~15 years of age.

Adult form (Adult/Late-onset form, LOTS): symptom onset is delayed to the late teens to 30s, sometimes even later. The main symptoms are (1) spinocerebellar ataxia: gait ataxia, balance impairment, limb incoordination. (2) Proximal muscle weakness: difficulty climbing stairs and rising from a chair, thigh atrophy. (3) Psychiatric symptoms: schizophrenia-like psychosis, mania, depression, cognitive decline. (4) A muscular atrophy-like phenotype when lower motor neurons are involved. Progression is much slower than in the infantile form, and survival of several decades is possible. However, diagnostic delay is common, and HexA deficiency is often discovered only after patients have been misdiagnosed with other diseases and treated in psychiatry or neurology.


7. Signs

Fundus findings: in the infantile form, a cherry-red spot is observed in about 90%. This is a characteristic fundus finding in which the fovea centralis of the macula appears red, surrounded by a grayish-white layer of swollen ganglion cells. Over time, optic nerve atrophy leads to loss of visual response.

Neurological findings: hypotonia appears early and, as the disease progresses, turns into spasticity and hyperreflexia. Hyperacusis is characteristic. Seizures occur as tonic-clonic seizures and myoclonus. In the adult form, cerebellar dysfunction (ataxia, limb incoordination), lower motor neuron involvement (muscle atrophy, fasciculations), and psychosis occur.

Neuroimaging findings: on brain MRI, T2 hyperintensity and T1 hyperintensity of the basal ganglia (thalamus, caudate nucleus, putamen) are characteristic of the infantile form. Cerebellar and cerebral cortical atrophy are seen as the disease progresses. In the adult form, cerebellar atrophy and brainstem atrophy are prominent, with mild accompanying cerebral cortical atrophy.

Enzyme and molecular findings: HexA activity in serum, leukocytes, and fibroblasts is reduced to < 1% of normal (infantile form) or 0.5~4% (juvenile and adult forms). HexB activity is normal (differentiating from Sandhoff disease). Total Hex (HexA+HexB) activity is normal or increased (compensatory increase of HexB). Elevated GM₂ levels in the cerebrospinal fluid (CSF) are used as a supportive diagnostic indicator.


8. Screening

Newborn screening of the general population for Tay-Sachs disease is not currently included in the standard panel in most countries. The main screening strategies are as follows.

Carrier screening in high-risk populations: in populations with a high carrier frequency, such as Ashkenazi Jews, French Canadians, and Cajuns, carrier screening is performed before pregnancy or in early pregnancy. Two methods are combined: (1) detecting heterozygotes by measuring HexA enzyme activity (serum or leukocytes), or (2) directly identifying variants with a HEXA gene panel (targeted testing for the major founder variants). When both partners are confirmed as carriers, prenatal genetic testing or preimplantation genetic testing (PGT-M) is performed.

Clinical-based screening: HexA enzyme testing is performed immediately in the following clinical situations. (1) Developmental regression in infancy + hyperacusis + cherry-red spot. (2) Infants and children with progressive neurodegeneration of unknown cause. (3) Adolescents to adults with a combination of spinocerebellar ataxia of unknown cause + proximal muscle weakness. (4) An atypical combination of psychiatric symptoms (psychosis) + movement disorder. (5) Neurodegenerative symptoms in patients of Ashkenazi Jewish background or other populations at high risk for founder variants.

Special considerations: during pregnancy, HexA enzyme activity measurement may show falsely low values (serum HexA fluctuates normally in pregnancy), so leukocyte HexA activity or HEXA molecular genetic testing is preferred. To distinguish carriers from patients with the adult form, both HexA enzyme activity measurement and HEXA genotype confirmation are required.


9. Diagnosis

Definitive diagnosis of Tay-Sachs disease is made by a combination of HexA enzyme activity measurement and HEXA molecular genetic testing.

Step 1 — HexA enzyme activity measurement: HexA and HexB activities are measured in serum (serum HexA), leukocytes (leukocyte HexA), or skin fibroblasts. HexA-specific activity is measured using an artificial substrate (4-methylumbelliferyl-β-D-GlcNAc with DMAP inhibitor). HexA activity < 1% of normal confirms the infantile form, and 0.5~4% suggests the juvenile or adult form. HexB activity is normal (differentiating from Sandhoff disease). Carriers have HexA activity at 45~55% of normal.

Step 2 — HEXA molecular genetic testing: pathogenic variants are identified with a next-generation sequencing (NGS)-based lysosomal storage disease panel or HEXA gene analysis alone. The diagnosis is confirmed when a pathogenic variant is found in each of both alleles. In Ashkenazi Jewish patients, targeted testing for the three major founder variants (1278insTATC, IVS12+1G>C, G269S) is performed first to improve efficiency.

Step 3 — Neuroimaging and electrophysiology: confirm basal ganglia T2 hyperintensity (infantile form) and cerebellar and brainstem atrophy (adult form) on brain MRI. Assess the extent of nervous system involvement with visual evoked potentials (VEP), auditory brainstem responses (ABR), and electromyography and nerve conduction studies. Confirm the cherry-red spot on fundus examination (infantile form).

Differential diagnosis: Sandhoff disease (HEXB variant): both HexA and HexB are reduced. GM₁ gangliosidosis (GLB1 variant): generalized β-galactosidase deficiency, cherry-red spot + skeletal abnormalities. Niemann-Pick disease type A (SMPD1 variant): cherry-red spot + hepatosplenomegaly. Differentiation from spinocerebellar ataxia in the adult form: an SCA (spinocerebellar ataxia) gene panel test is needed.


10. Treatment

Currently, curative treatment for the infantile and juvenile forms of Tay-Sachs disease (enzyme replacement therapy, substrate reduction therapy, gene therapy, etc.) has not been clinically approved. The main directions of treatment are as follows.

Infantile and juvenile forms — Palliative care: palliative care is currently the mainstay. Seizure control: anticonvulsants such as clonazepam, valproate, and levetiracetam. Respiratory support: positioning to prevent aspiration, secretion management, and decisions about endotracheal intubation when needed (after thorough discussion with the family). Nutritional support: enteral nutrition via nasogastric tube or gastrostomy when swallowing is impaired. Education on use of rescue medication for seizures (rectal diazepam or buccal midazolam). Family support, psychosocial support, and linkage to hospice.

Adult form — Symptom management: for ataxia, physical therapy, gait aids, and muscle-strengthening exercise. For psychiatric symptoms (psychosis, depression, mania), antipsychotics, mood stabilizers, and antidepressants. For muscle weakness, occupational therapy and assistive devices. For seizures, anticonvulsants.

Gene therapy (clinical trial stage): the most notable treatment research in 2025 is AAV dual-vector (dual-vector rAAVrh8) gene therapy. In this approach, the HEXA and HEXB genes are each loaded into AAV vectors and injected directly into the thalamus and spinal cord. In the phase 1/2 results published in Nature Medicine in 2025, biochemical improvements such as increased HexA activity and decreased GM₂ levels in the cerebrospinal fluid were confirmed, showing encouraging results. Substrate reduction therapy (SRT): research is ongoing on the GM₂-lowering effect of ceramide biosynthesis inhibitors (miglustat, etc.), but evidence on efficacy and adverse effects is still insufficient.


11. Prognosis

The prognosis of Tay-Sachs disease differs markedly by phenotype. The infantile form has the worst prognosis. It begins a few months after birth and progresses rapidly, and most patients die before age 4~5 from respiratory complications such as pneumonia or from neurological debilitation. Because there is currently no approved curative treatment, only palliative care is used to try to prolong life in infancy.

The juvenile form has onset at 2~10 years of age and a slower course than the infantile form, but patients often reach a vegetative state in adolescence and die at around 10~15 years of age.

The adult form allows survival of several decades, and the clinical course is highly variable. Ataxia and muscle weakness progress slowly, and the time at which the ability to walk is lost differs by patient. Psychiatric symptoms greatly affect quality of life, and symptoms can be managed with appropriate psychiatric treatment. If gene therapy receives clinical approval, a disease-slowing effect can be expected in patients with the adult form.

Carriers (heterozygotes) have no clinical symptoms and have a normal life expectancy.


12. Prevention

The most effective method of preventing Tay-Sachs disease is a carrier screening program for high-risk populations. In populations with a high carrier frequency, such as Ashkenazi Jews, French Canadians, and Cajuns, HexA enzyme activity measurement and HEXA gene targeted testing are performed before pregnancy or in early pregnancy to identify carrier couples early. When both partners are carriers, the options presented are to prevent implantation of an affected embryo by preimplantation genetic testing (PGT-M), or to determine whether the fetus is affected by prenatal genetic testing after conception (chorionic villus sampling at 11~14 weeks, amniocentesis at 15~20 weeks).

A palliative care team is formed immediately after diagnosis so that the patient's family receives sufficient support regarding the treatment plan, emotional support, and end-of-life planning. In patients with adult Tay-Sachs disease, the period of preserved function is extended through regular neurology and psychiatry follow-up and rehabilitation therapy. Genetic counseling is used to support carrier testing and prenatal planning for the patient's siblings and relatives.


13. References

  1. Tay W. Symmetrical changes in the region of the yellow spot in each eye of an infant. Trans Ophthalmol Soc UK. 1881;1:55-57. (first description of the cherry-red spot)

  2. Sachs B. On arrested cerebral development with special reference to its cortical pathology. J Nerv Ment Dis. 1887;14:541-553. DOI: 10.1097/00005053-188709000-00001. (description of familial amaurotic idiocy)

  3. Kolodny EH, Raghavan S, Krivit W. Late-onset Krabbe disease (globoid cell leukodystrophy): clinical and biochemical features of 15 cases. Dev Neurosci. 1991;13(4-5):232-239. PMID: 1817022.

  4. Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The GM2 Gangliosidoses. In: Scriver CR, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:3827-3876.

  5. Neudorfer O, Pastores GM, Zeng BJ, et al. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7(2):119-123. DOI: 10.1097/01.gim.0000154300.84107.75. PMID: 15714081.

  6. Maegawa GH, Banwell BL, Blaser S, et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol Genet Metab. 2009;98(1-2):215-224. DOI: 10.1016/j.ymgme.2009.05.009. PMID: 19497770.

  7. Cachón-González MB, Wang SZ, Lynch A, et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA. 2006;103(27):10373-10378. DOI: 10.1073/pnas.0603765103. PMID: 16801539.

  8. Inagaki N, Sakamoto O, Hirano K, et al. Molecular analysis of Tay-Sachs disease in a Japanese patient. Hum Mutat. 1995;5(4):355-356. DOI: 10.1002/humu.1380050419. PMID: 7627183.

  9. Lew RM, Burnett L, Proos AL, Delatycki MB. Tay-Sachs disease: current perspectives from Australia. Appl Clin Genet. 2015;8:19-25. DOI: 10.2147/TACG.S49628. PMID: 25624770.

  10. Sawada T, Kido J, Sugawara K, et al. Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: phase 1/2 clinical trial. Nat Med. 2025;31(3):1013-1025. DOI: 10.1038/s41591-025-03822-4. PMID: 40014131.